Showing posts with label Gatifloxacin. Show all posts
Showing posts with label Gatifloxacin. Show all posts

Tuesday, August 2, 2011

Will the Banned Rosiglitazone Reintroduced for the Neuropathic Pain


Banned drugs are in the news these days. Many drugs have been banned recently by the Drug Controller of India. DCI banned Gatifloxacin for systemic and oral use. Gatifloxacin eye drops were approved after the systemic use was banned.

Now the banned diabetes drug rosiglitazone is being explored as a short term pain medication in the US.

In patients who take rosiglitazone for glucose control, there is abundant evidence that rosiglitazone can increase the risk for heart failure, myocardial infarction, or death compared with its cousin pioglitazone.

In some patients this drug is the best bet. The US FDA recently released a rosiglitazone risk management strategy which limits the drug to patients already successfully treated with it or those for whom it's a last resort to control blood glucose medically.

The European Medicines Agency and the India DCI went further than its US counterpart by putting a complete halt on the sale of medications that contain rosiglitazone.

As per the new findings one can prevent development of nerve damage–induced neuropathic pain by controlling peripheral acute inflammation. The study will be published in the August issue of Anesthesia and Analgesia.

The preliminary exploration is based on a mouse model. Only 3-day administration of rosiglitazone immediately after nerve injury was sufficient to inhibit the development of chronic pain.

For pain management, patients would not need to take their medication daily like those with diabetes and might experience less risk because of it.

Local injection of rosiglitazone also produced similar effects as systemic administration. The side effects on the cardiovascular system can be avoided by local administration and by limiting duration for treatment to the acute phase.

Source: Anesth Analg. 2011;113:398-404.



Friday, July 22, 2011

Emedinews Edit: GATIFLOXACIN banned but not the eye drops

Gatifloxacin formulation for systemic use in human by any route including oral and injectable was prohibited for manufacture and distribution in the country by Ministry of Health, Government of India on 16.03.2011.
After the ban, the Drug Controller Department approved an eye formulation of gatifloxacin which caused confusion amongst the medical professionals.
Drug Controller of India issued a clarification dated 03.06.2011 with gatifloxacin ophthalmic formulations like eye drops and ointment which are topical formulations and are not for systemic use are not banned.